BioCentury reported that Eikon and Agomab raised $350 million combined in recent IPOs but saw share prices decline in the aftermarket. The public‑equity roundup highlighted uneven demand for biotech listings, with only a handful of new entrants enjoying first‑day gains. The performance illustrates fragile investor appetite for newly public biotech names despite healthy deal sizes. For VC‑backed companies and investment banks, aftermarket weakness will influence timing and valuation expectations for future equity raises.